<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0212222960
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FASENRA Pen
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BENRALIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        9386.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca Pharmaceuticals LP" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca Pharmaceuticals LP
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca AB 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DX10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Fasenra is</strong></p><p>Fasenra contains the active substance benralizumab, which is a monoclonal antibody, a type of protein that recognises and attaches to a specific target substance in the body. The target of benralizumab is a protein called interleukin‑5 receptor, which is found particularly on a type of white blood cell called an eosinophil.</p><p><br /><strong>What Fasenra is used for</strong></p><p><u>Asthma</u></p><p>Fasenra is used to treat <strong>severe eosinophilic asthma</strong> in adults. Eosinophilic asthma is a type of asthma where patients have too many eosinophils in the blood or lungs.</p><p>Fasenra is used together with other medicines to treat asthma (high doses of &lsquo;corticosteroid inhalers&rsquo; plus other asthma medicines) when the condition is not well controlled by those other medicines alone.</p><p><strong>&nbsp;</strong><u>Eosinophilic </u><u>granulomatosis with polyangiitis (EGPA)</u></p><p>Fasenra is used to treat EGPA in adults. EGPA is a condition where people have too many eosinophils in the blood and tissues and also have a form of vasculitis. This means there is inflammation of the blood vessels. This condition most commonly affects the lungs and sinuses but often affects other organs such as the skin, heart and kidneys.</p><p><strong>&nbsp;</strong></p><p><strong>How Fasenra works</strong></p><p>Eosinophils are white blood cells involved in asthma and EGPA inflammation. By attaching to the eosinophils, Fasenra helps to reduce their numbers and inflammation.</p><p><strong>&nbsp;</strong></p><p><strong>What are the benefits of using Fasenra</strong></p><p><u>Asthma</u></p><p>Fasenra may reduce the number of asthma attacks you are experiencing, help you breathe better and decrease your asthma symptoms. If you are taking medicines called &lsquo;oral corticosteroids&rsquo;, using Fasenra may also allow you to reduce the daily dose or stop the oral corticosteroids you need to control your asthma.</p><p>&nbsp;</p><p><u>EGPA</u></p><p>Fasenra can reduce symptoms and prevent flare-ups of EGPA. This medicine may also allow you to reduce the daily dose of oral corticosteroids you need to control your symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Fasenra:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>allergic</strong> to benralizumab or any of the other ingredients of this medicine (listed in section 6). <strong>Check with your doctor, nurse or pharmacist </strong>if you think this applies to you.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, nurse or pharmacist before you are given Fasenra:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a <strong>parasitic infection</strong> or if you live in an area where parasitic infections are common or you are travelling to such a region. This medicine may weaken your ability to fight certain types of parasitic infections,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had an <strong>allergic reaction to an injection or medicine in the past</strong> (see section 4 for symptoms of an allergic reaction).</p><p>Also, talk to your doctor, nurse or pharmacist when you are given Fasenra:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your <strong>asthma remains uncontrolled or worsens</strong> during treatment with this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any symptoms of an <strong>allergic reaction</strong> (see section 4). Allergic reactions have occurred in patients receiving this medicine.</p><p>Fasenra is <strong>not a rescue medicine.</strong> Do not use it to treat a sudden asthma attack.</p><p>&nbsp;</p><p><strong>Look out for signs of serious allergic reactions </strong></p><p>Fasenra can potentially cause serious allergic reactions. You must look out for signs of these reactions (such as hives, rash, breathing problems, fainting, dizziness, feeling lightheaded and/or swelling of your face, tongue or mouth) while you are taking Fasenra.</p><p>It is important that you talk to your doctor about how to recognise early symptoms of serious allergic reactions and how to manage these reactions if they occur.</p><p>In order to improve the traceability of biological medicinal products, record the name and the lot number, included on the outer carton and the label of the pre-filled syringe, every time you get a new package of Fasenra and provide this information when reporting any side effects.</p><p>&nbsp;</p><p><strong>Other medicines for asthma or EGPA</strong></p><p><strong>Do not suddenly stop taking</strong> or change the dose of your other medicines for your condition once you have started Fasenra.</p><p><strong>&nbsp;</strong>If your response to the treatment allows it, your doctor may try to reduce the dose of some of these medicines, especially ones called &lsquo;corticosteroids&rsquo;. This should be done gradually and under the direct supervision of your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor </strong>if you are taking, have recently taken or might take any other medicines before using Fasenra.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children below the age of 18 because the safety and benefits of this medicine are not known in this population.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast‑feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, <strong>ask your doctor for advice </strong>before using this medicine.</p><p>Do not use Fasenra if you are pregnant unless your doctor tells you otherwise. It is not known whether Fasenra could harm your unborn baby.</p><p>It is not known whether the ingredients of Fasenra can pass into breast milk. <strong>If you are breast‑feeding or plan to breast‑feed, talk to your doctor</strong>.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>It is unlikely that Fasenra will affect your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Fasenra contains Polysorbate 20</strong></p><p>This medicine contains 0.06 mg of polysorbate 20 (plant-derived) in each 30 mg pre-filled syringe. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.</p><p>&nbsp;</p><p><u>Asthma</u></p><p><strong>The recommended dose</strong> is an injection of 30&nbsp;mg. The first 3 injections are every 4 weeks. After this, injections are 30&nbsp;mg every 8&nbsp;weeks.</p><p>&nbsp;</p><p><u>EGPA</u></p><p><strong>The recommended dose</strong> is an injection of 30&nbsp;mg every 4&nbsp;weeks.</p><p>Fasenra is given as an injection just under the skin (subcutaneously). You and your doctor or nurse should decide if you should inject Fasenra yourself. You should not inject Fasenra yourself if you have not received Fasenra previously and if you had previous allergic reaction with Fasenra.</p><p>You or your caregiver should receive training on the right way to inject Fasenra. Read the &lsquo;Instructions for Use&rsquo; for the Fasenra Pen carefully before using Fasenra.</p><p>&nbsp;</p><p><strong>If you forget to use Fasenra</strong></p><p>If you have forgotten to inject a dose of Fasenra, talk to your doctor, pharmacist or nurse as soon as possible.</p><p>&nbsp;</p><p><strong>Stopping treatment with Fasenra</strong></p><p>Do not stop treatment with Fasenra unless your doctor advises you to. Interrupting or stopping the treatment with Fasenra may cause your asthma symptoms and attacks to come back.</p><p>If your asthma symptoms get worse while receiving injections of Fasenra, <strong>call your doctor.</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><u>Serious allergic reactions</u></strong></p><p><strong>Seek medical attention immediately </strong>if you think you may be having an allergic reaction. Such reactions may happen within hours or days after the injection.&nbsp;&nbsp;</p><p><strong>Not known</strong> (the frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylaxis</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms usually include:</p><p>o&nbsp;&nbsp; swelling of your face, tongue, or mouth</p><p>o&nbsp;&nbsp; breathing problems</p><p>o&nbsp;&nbsp; fainting, dizziness, feeling lightheaded (due to a drop in blood pressure)</p><p><strong>Common </strong>(these may affect <strong>up to 1 in 10</strong> <strong>people</strong>):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity reactions (hives, rash)</p><p><strong><u>Other side effects</u></strong><strong> </strong></p><p><strong>Common </strong>(these may affect <strong>up to 1 in 10</strong> <strong>people</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pharyngitis (sore throat)&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (high temperature)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reaction (for example pain, redness, itching, swelling near where the injection was given)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Fasenra Pen is for single-use only.</p><p>Do not use this medicine after the expiry date which is stated on the label and the carton after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>Store in the original package in order to protect from light.</p><p>Store in a refrigerator (2&nbsp;&deg;C to 8&nbsp;&deg;C).</p><p>The Fasenra Pen may be kept at room temperature up to 25&nbsp;&deg;C for a maximum of 14 days. After removal from the refrigerator, Fasenra must be used within 14 days or discarded, and the discard date should be written on the carton.</p><p>Do not shake, freeze or expose to heat.</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Fasenra Pen contains </strong></p><p>The active substance is benralizumab. One pre‑filled pen of 1&nbsp;mL solution contains 30&nbsp;mg benralizumab.</p><p>The other ingredients are histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 20 and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Fasenra is a solution which is colourless to yellow. It may contain particles.
Fasenra is available in a pack containing 1 pre filled pen. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p><strong>&nbsp;</strong></p><p>AstraZeneca AB</p><p>SE- 151 85</p><p>S&ouml;dert&auml;lje</p><p>Sweden</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>&nbsp;</p><p>AstraZeneca AB,</p><p>Gartunavagen.</p><p>SE-152 57</p><p>Sodertalje</p><p>Sweden</p><p>&nbsp;</p><p>Or</p><p>&nbsp;</p><p>Catalent Indiana, LLC</p><p>1300 South Patterson Drive</p><p>Bloomington, IN 47403</p><p>USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو فاسينرا</strong></p><p dir="RTL">يحتوي ال فاسينرا على مادة <strong>بنراليزوماب</strong> الفاعلة، وهي جسم مضاد أحاديّ النسيلة أي بروتين يتعرّف على مادة مُستهدَفة محددة في الجسم ويلتصق بها. يستهدف بنروالزوماب بروتين يٌدعى مستقيل إنترلوكين-5، والذي يتواجد بشك خاص في نوع من أنواع خلايا الدم البيضاء التي تٌدعى يوينية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما دواعي استعمال فاسينرا</strong></p><p dir="RTL"><u>الربو </u></p><p dir="RTL">يُستعمَل فاسينرا لعلاج <strong>الربو اليوزيني الشديد </strong>لدى البالغين. والربو اليوزيني نوع من الربو يرتفع لدى المرضى المصابين به عدد أليفات الإيوسين ارتفاعًا كبير جداً في الدم أو الرئتين. ويُستخدم فاسينرا جنباً إلى جنب مع أدوية أخرى لعلاج الربو (جرعات عالية من &quot;أجهزة استنشاق الستيرويدات القشرية&quot; زائد أدوية ربو أخرى) عندما لا تعود تلك الأدوية بمفردها قادر على التحكم في الحالة.</p><p dir="RTL">الورم الحبيبي اليوزيني مع التهاب الأوعية الدموية (EGPA)</p><p dir="RTL">يستخدم فاسينرا لعلاج الورم الحبيبي اليوزيني مع التهاب الأوعية الدموية (EGPA) لدى البالغين. الورم الحبيبي اليوزيني هو حالة حيث يكون لدى الأشخاص عدد كبير جدًا من الخلايا الحمضية في الدم والأنسجة ويعانون أيضًا من شكل من أشكال التهاب الأوعية الدموية. هذا يعني وجود التهاب في الأوعية الدموية. تؤثر هذه الحالة بشكل شائع على الرئتين والجيوب الأنفية ولكنها غالبًا ما تؤثر على أعضاء أخرى مثل الجلد والقلب والكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة عمل فاسينرا</strong></p><p dir="RTL">اليوزينيات نوع من أنواع خلايا الدم البيضاء لها علاقة بالتهاب الربو والورم الحبيبي اليوزيني مع التهاب الأوعية الدموية (EGPA). ويساعد فاسينرا على تقليل عدد اليوزينيات والالتهابات من خلال التعلق بها.</p><p dir="RTL">الورم الحبيبي اليوزيني مع التهاب الأوعية الدموية (EGPA)</p><p dir="RTL">يمكن أن يقلل فاسينرا من الأعراض ويمنع تفاقم المرض. قد يسمح لك هذا الدواء أيضًا بتقليل الجرعة اليومية من الكورتيكوستيرويدات الفموية التي تحتاجها للسيطرة على الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما فوائد استعمال فاسينرا</strong></p><p dir="RTL">قد يٌخفض فاسينرا من عدد نوبات الربو التي تعانيها، ويساعدك على التنفس بشكل أفضل ويحد من أعراض الربو لديك. إذا كنت تتناول أدوية تٌدعى &quot;ستيرويدات قشرية فموية&quot;، فقد يسمح لك استعمال فاسينرا أيضاً بتخفيض جرعتك اليومية من الستيرويدات القشرية الفموية التي تحتاج إليها للتحكم في الربو إو إيقاف تناولها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية لمادة بنراليزوماب أو أي من مكونات هذا الدواء الأخرى (المذكورة في القسم 6). استشر طبيبك أو الممرضة أو الصيدلي إذا كنت تظن أن ذلك ينطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الممرضة أو الصيدلي قبل إعطائك فاسينرا في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تعرّضك من قبل لأي أعراض ردّ فعل تحسسي (انظر القسم 4 &quot;الآثار الجانبية المحتملة&quot;). لأن بعض المرضى الذين تلقّوا هذا الدواء أصيبوا بردود فعل تحسسية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى طُفَيلية أو تعيش في منطقة تشيع فيها حالات العدوى الطُفَيلية أو كنت في طريقك للسفر إلى منطقة من هذه المناطق، لأن هذا الدواء قد يضعف قدرتك على مقاومة أنواع معينة من العدوى الطفيلية.</p><p dir="RTL">كذلك، تحدث إلى طبيبك أو الممرضة أو الصيدلي عند إعطائك فاسينرا في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يتم التحكم في الربو الذي تعانيه أو تفاقهم خلال علاجك بهذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت لأي أعراض رد فعلي تحسسي) انظر القسم 4). تعرض بعض المرضى الذين تلقوا هذا الدواء لردود فعل تحسسية.</p><p dir="RTL">فاسينرا ليس دواء إنقاذ. لا تستخدمه لعلاج نوبة ربو مفاجئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">انظر الى بعض العلامات التحسسية الخطيرة</p><p dir="RTL">يمكن ان يسبب فاسينرا ردود فعل تحسسية خطيرة. يجب أن تنظر الى هذه التفاعلات مثل (الشرى، الطفح الجلدي، مشاكل التنفس، الإغماء، الدوخة، الشعور بالدوار، أو تورم في الوجه أو اللسان أو الفم) أثناء تناولك فاسينرا.</p><p dir="RTL">من المهم ان تتحدث مع طبيبك حول كيفية التعرف على الأعراض المبكرة للتفاعلات التحسسية الخطيرة وكيفية إدارة هذه التفاعلات إذا حدثت.</p><p dir="RTL">من أجل تحسين إمكانية تتبع المنتجات الطبية البيولوجية، قم بتسجيل الاسم ورقم الدفعة، الموجودين على الكرتون الخارجي وملصق المحقنة المعبأة مسبقًا، في كل مرة تحصل فيها على عبوة جديدة من فاسينرا وقم بتوفير هذه المعلومات عند الإبلاغ عن أي آثار جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول/استخدام أدوية أخرى للربو او الورم الحبيبي اليوزيني مع التهاب الأوعية الدموية (</strong><strong>EGPA</strong><strong>)</strong></p><p dir="RTL"><strong>لا تتوقف بشكل مفاجئ عن تناول </strong>الأدوية الأخرى لحالتك بمجرد أن تبدأ بتناول فاسينرا.</p><p dir="RTL">فهذه الأدوية (وخاصة الأنواع التي تنتمي لفئة <em>الكورتيكوستيرويدات</em>) يجب إيقافها تدريجياً، وتحت الإشراف المباشر لطبيبك واستناداً إلى مدى استجابتك لدواء فاسينرا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تعطي هذا الدواء أي شخص يقل عمره عن 18 عامًا. ويرجع ذلك إلى عدم وجود معلومات عن مدى فعاليته في هذه الفئة العمرية.</p><p dir="RTL"><strong>أخبر طبيبك إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى قبل استخدام </strong>فاسينرا<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">إذا كنتِ حاملاً أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، <strong>فاستشيري طبيبكِ </strong>قبل استخدام هذا الدواء.</p><p dir="RTL">لا تستعملي فاسينرا إذا كنت حاملاً مالم يشير عليك طبيبك بخلاف ذلك. من غير المعروف ما إذا كان فاسينرا قد يلحق الأذى بجنينك أم لا.</p><p dir="RTL">من غير المعروف ما إذا كانت مكونات فاسينرا قد تعبر الى حليب الأم أم لا. <strong>إذا كنت ترضعين أو تخططين للإرضاع، فتحدثي إلى طبيبك.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر فاسينرا في قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فاسينرا على بوليسوربات 20</strong></p><p dir="RTL">يحتوي هذا الدواء على 0.06 مجم من بوليسوربات 20 (مشتق من النباتات) في كل حقنة مملوءة مسبقًا 30 مجم. قد تسبب بوليسوربات تفاعلات حساسية. أخبر طبيبك إذا كان لديك أي حساسية معروفة</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعمل هذا الدواء دائمًا حسب توجيهات الطبيب تمامًا. واستشر طبيبك أو الصيدلي أو الممرضة إذا لم تكن متأكداً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الربو</p><p dir="RTL"><strong>&nbsp;الجرعة الموصى بها </strong>30&nbsp;ملغ كل 4 أسابيع لأول 3 مرات حقن، ثم كل 8 أسابيع بعد ذلك.</p><p dir="RTL"><strong>الورم الحبيبي اليوزيني مع التهاب الأوعية الدموية (</strong><strong>EGPA</strong><strong>)</strong></p><p dir="RTL"><strong>الجرعة الموصى بها هي حقنة 30 ملغ كل 4 أسابيع.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعطى فاسينرا بالحقن تحت الجلد. وعليك أن تقرر أنت وطبيبك أو الممرضة ما إذا كنت ستتولى حقن نفسك بفاسينرا. يجب أن تحصل أنت أو من يتولى رعايتك على تدريب حول الطريقة الصحيحة لإعداد وحقن</p><p dir="RTL">فاسينرا. اقرأ جيداً &quot;تعليمات الاستخدام&quot; قبل استخدام فاسينرا.</p><p dir="RTL">انظر &quot;تعليمات استخدام محقنة فاسينرا المعبأة مسبقاً&quot; أو &quot;تعليمات استخدام محقنة فاسينرا الذاتية&quot; (قلم فاسينرا).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول إحدى الجرعات</strong></p><p dir="RTL">في حالة نسيان حقن جرعة من فاسينرا، استشر الطبيب أو الصيدلي أو الممرضة في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار التوقف عن جرعات علاج فاسينرا</strong></p><p dir="RTL">لا تتوقف عن الحصول على جرعات فاسينرا إلا بناء على توصية من الطبيب. قد يؤدي الانقطاع عن استخدام فاسينرا أو إيقافه إلى عودة أعراض الربو ونوباته التي كانت تصيبك.</p><p dir="RTL">إذا تفاقمت أعراض الربو التي تأتيك في أثناء الحصول على جرعات فاسينرا، <strong>فاتصل بطبيبك</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي أو الممرضة إذا كانت لديك أي أسئلة أخرى حول استعمال هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا العقار، شأنه شأن جميع العقاقير، آثاراً جانبية، على الرغم من أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية</strong></p><p dir="RTL">قد يتعرّض بعض الأشخاص لردود فعل تحسسية. وردود الفعل هذه قد تحدث بعد ساعات أو أيام من الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويمكن أن تشمل الأعراض:</p><p dir="RTL"><strong>الأعراض الشائعة </strong>(قد تصيب <strong>ما لا يزيد عن شخص واحد من كل 10 أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية &nbsp;(شَرَى ، طفح جلدي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض غير معروف معدل حدوثها </strong>(لا يمكن تقدير معدل الحدوث من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو اللسان أو الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء، والدوار، والدوخة (نتيجة لانخفاض ضغط الدم)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اطلب العناية الطبية على الفور إذا كنت تظن أنك تمر بردّ فعل تحسسي. </strong>إذا كنت قد تعرضت من قبل لرد فعل مماثل لأي حقنة أو دواء، <strong>فأخبر طبيبك قبل أن تحصل على جرعات فاسينرا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى:</strong></p><p dir="RTL"><strong>الآثار الشائعة (</strong>قد تصيب <strong>ما لا يزيد عن شخص واحد من كل 10 أشخاص</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البلعوم (احتقان الحلق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحُمّى (ارتفاع درجة الحرارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردّ فعل في مكان الحقن (مثل ألم أو احمرار أو حكة أو تورّم بالقرب من مكان الحقن)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أي أعراض جانبية غير مذكورة في هذه النشرة، فيُرجى إخبار طبيبك/طبيب أسنانك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن متناول الأطفال وأعينهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ان قلم فاسينرا هو للإستخدام الواحد فقط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المكتوب على الملصق الداخلي والعبوة الخارجية &nbsp;(EXP). يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المدوّن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ الدواء في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ الدواء في الثلاجة (في درجة حرارة تتراوح ما بين درجتين و8 درجات مئوية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن حفظ فاسينرا في درجة حرارة الغرفة لمدة 14&nbsp;يوماً كحدٍ أقصى على ألّا تتجاوز حرارة الغرفة 25 درجة مئوية. وبعد إخراج فاسينرا من الثلاجة، يجب استخدامه خلال 14 يوماً أو التخلص منه. يجب ان يكتب تاريخ التخلص على الكرتون .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ترج الدواء أو تجمده أو تعرضه للحرارة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي بنراليزوماب. يحتوي قلم واحد مملوء مسبقًا بمحلول سعة 1 مل على 30 ملغ من بنراليزوماب.</p><p dir="RTL">المكونات الأخرى هي هيستيدين، هيدروكلوريد هيستيدين أحادي الهيدرات، تريهالوز ثنائي الهيدرات، بوليسوربات 20 (E 432) وماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فاسينرا هو محلول عديم اللون إلى أصفر اللون. قد يحتوي على جزيئات.</p><p dir="RTL">فاسينرا متوفر في عبوة تحتوي على قلم واحد مملوء مسبقًا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">أسترازينيكا إيه بي</p><p dir="RTL">SE- 151 85</p><p>سودرتاليا</p><p>السويد</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التصنيع </strong></p><p dir="RTL">&nbsp;أسترازينيكا إيه بي,</p><p dir="RTL">&nbsp;جارتونافاجن.</p><p dir="RTL">SE-152 57</p><p dir="RTL">سودرتاليا &nbsp;</p><p dir="RTL">السويد</p><p dir="RTL">&nbsp;</p><p dir="RTL">او</p><p dir="RTL">&nbsp;</p><p dir="RTL">كاتالنت إنديانا، ذ.م.م.</p><p dir="RTL">1300 ساوث باترسون درايف</p><p dir="RTL">بلومنجتون، إنديانا 47403</p><p dir="RTL">أمريكا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2024 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fasenra 30 mg solution for injection in pre filled syringe
Fasenra 30 mg solution for injection in pre filled pen

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pre filled syringe
Each pre filled syringe contains 30 mg benralizumab* in 1 mL.

Pre filled pen
Each pre filled pen contains 30 mg benralizumab* in 1 mL.

*Benralizumab is a humanised monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection) in pre filled syringe
Solution for injection (injection) in pre filled pen (Fasenra Pen)

Clear to opalescent, colourless to yellow solution and may contain translucent or white to off white particles.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Asthma</p><p>Fasenra is indicated as an add‑on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long‑acting &beta;‑agonists (see section 5.1).</p><p>&nbsp;</p><p><u>Eosinophilic granulomatosis with polyangiitis (EGPA)</u></p><p>Fasenra is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fasenra treatment should be initiated by a physician experienced in the diagnosis and treatment of conditions for which benralizumab is indicated (see section&nbsp;4.1) .</p><p>After proper training in the subcutaneous injection technique and education about signs and symptoms of hypersensitivity reactions (see section&nbsp;4.4), patients with no known history of anaphylaxis or their caregivers may administer Fasenra if their physician determines that it is appropriate, with medical follow-up as necessary. Self-administration should only be considered in patients already experienced with Fasenra treatment.</p><p>&nbsp;</p><p><u>Posology</u></p><p>Fasenra is intended for long‑term treatment. A decision to continue the therapy should be made at least annually based on disease severity, level of exacerbation control and blood eosinophil counts.</p><p>&nbsp;</p><p><em>Asthma</em></p><p>The recommended dose of benralizumab is 30&nbsp;mg by subcutaneous injection every 4&nbsp;weeks for the first 3&nbsp;doses, and then every 8&nbsp;weeks thereafter.</p><p>&nbsp;</p><p><em>EGPA</em></p><p>The recommended dose of benralizumab is 30&nbsp;mg by subcutaneous injection every 4&nbsp;weeks.</p><p>Patients who develop life-threatening manifestations of EGPA should be evaluated for the need for continued therapy, as Fasenra has not been studied in this population.</p><p>&nbsp;</p><p><em>Missed Dose</em></p><p>If an injection is missed on the planned date, dosing should resume as soon as possible on the indicated regimen; a double dose must not be administered.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is required for elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em>Renal and hepatic impairment</em></p><p>No dose adjustment is required for patients with renal or hepatic impairment (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of Fasenra in children and adolescents aged 6 to 17&nbsp;years with asthma has not been established.</p><p>Currently limited data in children 6 to 11 years old and data in adolescents aged 12 to 17 are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p>The safety and efficacy of Fasenra in children less than 6 years with asthma have not been established. No data are available.</p><p>The safety and efficacy of Fasenra in children and adolescents less than 18&nbsp;years with EGPA have not been established.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>This medicinal product is administered as a subcutaneous injection.<em> </em></p><p>It should be injected into the thigh or abdomen. If the healthcare professional or caregiver administers the injection, the upper arm can also be used. It should not be injected into areas where the skin is tender, bruised, erythematous, or hardened.</p><p>Comprehensive instructions for administration using the pre‑filled syringe/pre‑filled pen are provided in the &lsquo;Instructions for Use&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Asthma exacerbations</u></p><p>Fasenra should not be used to treat acute asthma exacerbations.</p><p>Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment.</p><p>&nbsp;</p><p><u>Corticosteroids</u></p><p>Abrupt discontinuation of corticosteroids after initiation of Fasenra therapy is not recommended. Reduction in corticosteroid doses, if appropriate, should be gradual and performed under the supervision of a physician.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions </u></p><p>Acute systemic reactions including anaphylactic reactions and hypersensitivity reactions (e.g.&nbsp;urticaria, papular urticaria, rash) have occurred following administration of benralizumab (see section&nbsp;4.8). These reactions may occur within hours of administration, but in some instances have a delayed onset (i.e.&nbsp;days).</p><p>A history of anaphylaxis unrelated to benralizumab may be a risk factor for anaphylaxis following Fasenra administration (see section&nbsp;4.3). In line with clinical practice, patients should be monitored for an appropriate time after administration of Fasenra.</p><p>In the event of a hypersensitivity reaction, Fasenra should be discontinued permanently and appropriate therapy should be initiated.</p><p>&nbsp;</p><p><u>Parasitic (Helminth) infection</u></p><p>Eosinophils may be involved in the immunological response to some helminth infections. Patients with known helminth infections were excluded from participation in clinical trials. It is unknown if benralizumab may influence a patient&rsquo;s response against helminth infections.</p><p>Patients with pre‑existing helminth infections should be treated before initiating therapy with benralizumab. If patients become infected, while receiving treatment and do not respond to anti‑helminth treatment, therapy with benralizumab should be discontinued until infection resolves.</p><p>&nbsp;</p><p><u>Organ threatening or life-threatening EGPA</u></p><p>Fasenra has not been studied in patients with active organ threatening or life-threatening manifestations of EGPA (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. In a randomised, double-blind parallel-group study of 103 patients aged between 12 and 21 years with severe asthma, the humoral antibody responses induced by seasonal influenza virus vaccination do not appear to be affected by benralizumab treatment. An effect of benralizumab on the pharmacokinetics of co‑administered medicinal products is not expected (see section&nbsp;5.2).</p><p>Cytochrome P450 enzymes, efflux pumps and protein‑binding mechanisms are not involved in the clearance of benralizumab. There is no evidence of IL‑5R&alpha; expression on hepatocytes. Eosinophil depletion does not produce chronic systemic alterations of proinflammatory cytokines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There is a limited amount of data (less than 300 pregnancy outcomes) from the use of benralizumab in pregnant women.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>Monoclonal antibodies, such as benralizumab, are transported across the placenta linearly as pregnancy progresses; therefore, potential exposure to the fetus is likely to be greater during the second and third trimester of pregnancy.</p><p>As a precautionary measure, it is preferable to avoid the use of Fasenra during pregnancy. Its administration to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>It is unknown whether benralizumab or its metabolites are excreted in human or animal milk. A risk to the breast‑fed child cannot be excluded.</p><p>A decision must be made whether to discontinue breast‑feeding or to discontinue/abstain from using Fasenra taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no fertility data in humans. Animal studies showed no adverse effects of benralizumab treatment on fertility (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fasenra has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety profile of benralizumab in asthma and EGPA are similar.</p><p>The most commonly reported adverse reactions during treatment in asthma are headache (8%) and pharyngitis (3%). The most commonly reported adverse reaction in EGPA is headache (17%). Cases of anaphylactic reaction of varied severity have been reported for benralizumab.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions have been reported with benralizumab during clinical studies in asthma and EGPA and from post-marketing experience. The frequency of adverse reactions is defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); and not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table </strong><!--[if supportFields]><span style='mso-bookmark:
_Ref462755986'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref462755986'><b style='mso-bidi-font-weight:normal'><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span
style='mso-spacerun:yes'> </span>SEQ Table \* ARABIC <span style='mso-element:
field-separator'></span></span></b></span><![endif]--><strong>1</strong><!--[if supportFields]><span
style='mso-bookmark:_Ref462755986'></span><span style='mso-element:field-end'></span><![endif]--><strong>. </strong><strong>Tabulated list of adverse reactions&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:677px"><tbody><tr><td style="vertical-align:top; width:350px"><p><strong>MedDRA System organ class</strong></p></td><td style="vertical-align:top; width:201px"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top; width:123px"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top; width:350px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:201px"><p>Pharyngitis<sup>a</sup></p></td><td style="vertical-align:top; width:123px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:350px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:201px"><p>Hypersensitivity reactions<sup>b</sup></p><p>Anaphylactic reaction</p></td><td style="vertical-align:top; width:123px"><p>Common</p><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:350px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:201px"><p>Headache<sup>c</sup></p></td><td style="vertical-align:top; width:123px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:350px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:201px"><p>Pyrexia</p><p>Injection site reaction<sup>d</sup></p></td><td style="vertical-align:top; width:123px"><p>Common</p></td></tr></tbody></table><p><sup>a.</sup> Pharyngitis was defined by the following grouped preferred terms: &lsquo;Pharyngitis&rsquo;, &lsquo;Pharyngitis bacterial&rsquo;, &lsquo;Viral pharyngitis&rsquo;, &lsquo;Pharyngitis streptococcal&rsquo;.<br /><sup>b.</sup> Hypersensitivity reactions were defined by the following grouped preferred terms: &lsquo;Urticaria&rsquo;, &lsquo;Papular urticaria&rsquo;, and &lsquo;Rash&rsquo;. For examples of the associated manifestations reported and a description of the time to onset, see section 4.4.</p><p><sup>c. </sup>Very common in EGPA study.</p><p><sup>d.</sup> See &lsquo;Description of selected adverse reaction&rsquo;.</p><p>&nbsp;</p><p><u>Description of selected adverse reaction</u></p><p><em>Injection site reactions </em></p><p>In placebo‑controlled asthma studies, injection site reactions (e.g. pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with the recommended benralizumab dose compared with 1.9% in patients treated with placebo. The events were transient in nature.</p><p>&nbsp;</p><p><u>Long-term safety </u></p><p>In a 56-week extension trial (Trial 4) in patients with asthma from Trials&nbsp;1, 2 and 3, 842&nbsp;patients were treated with Fasenra at the recommended dose and remained in the trial. The overall safety profile was similar to the asthma trials described above. Additionally, in an open-label safety extension trial (Trial 5) in patients with asthma from previous trials, 226 patients were treated with Fasenra at the recommended dose for up to 43 months. Combined with the treatment period in previous studies, this corresponds to a median follow-up of 3.4 years (range 8.5 months &ndash; 5.3 years). The safety profile during this follow-up period was consistent with the known safety profile of Fasenra.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>There are limited data in paediatric patients. There were 108 adolescents aged 12 to 17 with asthma enrolled in the phase 3 trials (Trial 1: n=53, Trial 2: n=55). Of these, 46 received placebo, 40 received benralizumab every 4 weeks for 3 doses, followed by every 8 weeks thereafter, and 22 received benralizumab every 4 weeks. Adolescent patients aged 12 to 17 (n=86) from Trials 1 and 2 continued the treatment with benralizumab in Trial 4 for up to 108 weeks. The frequency, type and severity of adverse reactions in the adolescent population were observed to be similar to those seen in adults.</p><p>In an open-label, uncontrolled pharmacokinetic and pharmacodynamic study of 48 weeks duration in a limited number of paediatric patients (n=28) with uncontrolled severe asthma, the safety profile for patients aged 6 to 11 years old was similar to the adult and adolescent population (see section 4.2).</p><p>&nbsp;</p><p>- To report any side effect(s):</p><p>&bull;&nbsp;&nbsp; Saudi Arabia</p><table border="0" cellspacing="0" cellpadding="0" style="width:570px"><tbody><tr><td style="vertical-align:bottom"><p></p></td><td style="vertical-align:bottom"><p>The National Pharmacovigilance Centre (NPC):</p></td></tr><tr><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>SFDA Call Center: 19999</p></td></tr><tr><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>E-mail: npc.drug@sfda.gov.sa</p></td></tr><tr><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&bull;&nbsp;&nbsp; Other GCC states:</p><table border="0" cellspacing="0" cellpadding="0" style="width:572px"><tbody><tr><td style="vertical-align:bottom"><p>-</p></td><td style="vertical-align:bottom"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses of up to 200&nbsp;mg were administered subcutaneously in clinical trials to patients with eosinophilic asthma without evidence of dose‑related toxicities.</p><p>There is no specific treatment for an overdose with benralizumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases, ATC code: R03DX10</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Benralizumab is an anti‑eosinophil, humanised afucosylated, monoclonal antibody (IgG1, kappa). It specifically binds to the alpha subunit of the human interleukin‑5 receptor (IL‑5R&alpha;). The IL‑5 receptor is specifically expressed on the surface of eosinophils and basophils. The absence of fucose in the Fc domain of benralizumab results in high affinity for FcɣRIII receptors on immune effector cells such as natural killer (NK) cells. This leads to apoptosis of eosinophils and basophils through enhanced antibody‑dependent cell‑mediated cytotoxicity (ADCC), which reduces eosinophilic inflammation.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em><u>Effect on blood eosinophils</u></em></p><p>In patients with asthma, treatment with benralizumab results in near complete depletion of blood eosinophils within 24 hours following the first dose which is maintained throughout treatment. The depletion of blood eosinophils is accompanied by a reduction in serum eosinophil granule proteins eosinophil derived neurotoxin [EDN] and eosinophil cationic protein [ECP] and a reduction in blood basophils.</p><p>In patients with EGPA, depletion of blood eosinophils was consistent with the effect observed in asthma trials. Blood eosinophil depletion was seen at the first observed time point, 1 week of treatment, and was maintained throughout the 52‑week treatment period.</p><p>&nbsp;</p><p><em><u>Effect on eosinophils in the airway mucosa</u></em></p><p>The effect of benralizumab on eosinophils in the airway mucosa in asthmatic patients with elevated sputum eosinophil counts (at least 2.5%) was evaluated in a 12‑week, phase 1, randomised, double-blind, placebo-controlled clinical study with benralizumab 100 or 200 mg administered subcutaneously. In this study there was a median reduction from baseline in airway mucosa eosinophils of 96% in the benralizumab-treated group compared to a 47% reduction in the placebo group (p=0.039).</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p><u>Asthma</u></p><p>The efficacy of benralizumab was evaluated in 3 randomised, double‑blind, parallel‑group, placebo‑controlled clinical trials between 28 to 56&nbsp;weeks duration, in patients aged 12 to 75&nbsp;years.</p><p>In these studies, benralizumab was administered at a dose of 30&nbsp;mg once every 4&nbsp;weeks for the first 3&nbsp;doses, and then every 4 or 8&nbsp;weeks thereafter as add‑on to background treatment and was evaluated in comparison with placebo.</p><p>The two exacerbation trials, SIROCCO (Trial 1) and CALIMA (Trial 2), enrolled a total of 2,510 patients with severe uncontrolled asthma, 64% females, with a mean age of 49&nbsp;years. Patients had a history of 2 or more asthma exacerbations requiring oral or systemic corticosteroid treatment (mean of 3) in the past 12&nbsp;months, Asthma Control Questionnaire‑6 (ACQ‑6) score of 1.5 or more at screening, and reduced lung function at baseline (mean predicted pre‑bronchodilator forced expiratory volume in 1 second [FEV<sub>1</sub>] of 57.5%), despite regular treatment with high‑dose inhaled corticosteroid (ICS) (Trial 1) or with medium or high‑dose ICS (Trial 2) and a long‑acting &beta;‑agonist (LABA); at least one additional controller was administered to 51% and 41% of these patients, respectively.</p><p>For the oral corticosteroid (OCS) reduction trial ZONDA (Trial 3), a total of 220 asthma patients (61% female; mean age of 51 years) were enrolled; they were treated with daily OCS (8 to 40&nbsp;mg per day; median of 10&nbsp;mg) in addition to regular use of high‑dose ICS and LABA with at least one additional controller to maintain asthma control in 53% of the cases. The trial included an 8‑week run‑in period during which the OCS was titrated to the minimum effective dose without losing asthma control.<em> </em>Patients had blood eosinophil counts &ge;150&nbsp;cells/&mu;L and a history of at least one exacerbation in the past 12&nbsp;months.</p><p>While 2 dose regimens were studied in Trials 1, 2, and 3, the recommended dose regimen is benralizumab administered every 4&nbsp;weeks for the first 3 doses, then every 8&nbsp;weeks thereafter (see section 4.2) as no additional benefit was observed by more frequent dosing. The results summarised below are those for the recommended dose regimen.</p><p>&nbsp;</p><p><em><u>Exacerbation trials</u></em></p><p>The primary endpoint was the annual rate of clinically significant asthma exacerbations in patients with baseline blood eosinophil counts &ge;300&nbsp;cells/&mu;L who were taking high‑dose ICS and LABA. Clinically significant asthma exacerbation was defined as worsening of asthma requiring use of oral/systemic corticosteroids for at least 3&nbsp;days, and/or emergency department visits requiring use of oral/systemic corticosteroids and/or hospitalisation. For patients on maintenance OCS, this was defined as a temporary increase in stable oral/systemic corticosteroids for at least 3&nbsp;days or a single depo‑injectable dose of corticosteroids.</p><p>In both trials, patients receiving benralizumab experienced significant reductions in annual exacerbation rates compared to placebo in patients with blood eosinophils &ge;300&nbsp;cells/&mu;L. In addition, change from&nbsp;baseline in mean FEV<sub>1</sub> showed benefit as early as 4 weeks, which was maintained through to end of treatment (<strong>Table 2</strong>).&nbsp;</p><p>Reductions in exacerbation rates were observed irrespective of baseline eosinophil count; however, increasing baseline eosinophil counts was identified as a potential predictor of improved treatment response particularly for FEV<sub>1</sub>.</p><p>&nbsp;</p><p><strong>Table 2. Results of annual exacerbation rate and lung function at end of treatment of Trial 1 and 2 by eosinophil count</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Trial 1</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Trial 2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Benralizumab</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Benralizumab</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood eosinophil count &ge;300 cells/&mu;L<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>n =267</p></td><td style="vertical-align:top"><p>n =267</p></td><td style="vertical-align:top"><p>n =239</p></td><td style="vertical-align:top"><p>n =248</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Clinically significant exacerbations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rate</p></td><td style="vertical-align:top"><p>0.74</p></td><td style="vertical-align:top"><p>1.52</p></td><td style="vertical-align:top"><p>0.73</p></td><td style="vertical-align:top"><p>1.01</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td colspan="2" style="vertical-align:top"><p>-0.78</p></td><td colspan="2" style="vertical-align:top"><p>-0.29</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.49 (0.37, 0.64)</p></td><td colspan="2" style="vertical-align:top"><p>0.72 (0.54, 0.95)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td><td colspan="2" style="vertical-align:top"><p>0.019</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Pre-bronchodilator FEV<sub>1 </sub></strong><strong>(L) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p></td><td style="vertical-align:top"><p>1.660</p></td><td style="vertical-align:top"><p>1.654</p></td><td style="vertical-align:top"><p>1.758</p></td><td style="vertical-align:top"><p>1.815</p></td></tr><tr><td style="vertical-align:top"><p>Improvement from baseline</p></td><td style="vertical-align:top"><p>0.398</p></td><td style="vertical-align:top"><p>0.239</p></td><td style="vertical-align:top"><p>0.330</p></td><td style="vertical-align:top"><p>0.215</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)<em><sup> </sup></em></p></td><td colspan="2" style="vertical-align:top"><p>0.159 (0.068, 0.249)</p></td><td colspan="2" style="vertical-align:top"><p>0.116 (0.028, 0.204)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.001</p></td><td colspan="2" style="vertical-align:top"><p>0.010</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood eosinophil<em> </em>count &lt;300 cells/&mu;L<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>n =131</p></td><td style="vertical-align:top"><p>n =140</p></td><td style="vertical-align:top"><p>n =125</p></td><td style="vertical-align:top"><p>n =122</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Clinically significant exacerbations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rate</p></td><td style="vertical-align:top"><p>1.11</p></td><td style="vertical-align:top"><p>1.34</p></td><td style="vertical-align:top"><p>0.83</p></td><td style="vertical-align:top"><p>1.38</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td colspan="2" style="vertical-align:top"><p>-0.23</p></td><td colspan="2" style="vertical-align:top"><p>-0.55</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.83 (0.59, 1.16)</p></td><td colspan="2" style="vertical-align:top"><p>0.60 (0.42, 0.86)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Pre-bronchodilator FEV<sub>1 </sub></strong><strong>(L)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean change</p></td><td style="vertical-align:top"><p>0.248</p></td><td style="vertical-align:top"><p>0.145</p></td><td style="vertical-align:top"><p>0.140</p></td><td style="vertical-align:top"><p>0.156</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.102 (-0.003, 0.208)</p></td><td colspan="2" style="vertical-align:top"><p>-0.015 (-0.127, 0.096)</p></td></tr></tbody></table><p><sup>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Intent-to-treat population (patients on high‑dose ICS and blood eosinophils &ge;300 cells/&mu;L).</p><p><sup>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Not powered to detect a treatment difference in patients with blood eosinophils &lt;300 cells/&mu;L.</p><p>&nbsp;</p><p>Across Trials 1 and 2 combined, there was a numerically greater exacerbation rate reduction and greater improvements in FEV<sub>1</sub> with increasing baseline blood eosinophils.</p><p>The rate of exacerbations requiring hospitalisation and/or emergency room visits for patients receiving benralizumab compared to placebo for Trial 1 were 0.09 versus 0.25 (rate ratio 0.37, 95% CI: 0.20, 0.67, p=&lt;0.001) and for Trial 2 were 0.12 versus 0.10 (rate ratio 1.23, 95% CI: 0.64, 2.35, p=0.538). In Trial 2, there were too few events in the placebo treatment arm to draw conclusions for exacerbations requiring hospitalisation or emergency room visits.</p><p>In both Trials 1 and 2, patients receiving benralizumab experienced statistically significant reductions in asthma symptoms (Total Asthma Score) compared to patients receiving placebo. Similar improvement in favour of benralizumab was observed for the ACQ‑6 and Standardised Asthma Quality of Life Questionnaire for 12&nbsp;Years and Older (AQLQ(S)+12) (<strong>Table 3</strong>).</p><p><strong>&nbsp;</strong></p><p><strong>Table 3. Treatment difference in mean change from baseline in total asthma symptom score, ACQ‑6 and AQLQ(s)+12 at end of treatment - Patients on high‑dose ICS and blood eosinophils &ge;300&nbsp;cells/&mu;L</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:589px"><thead><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Trial 1</p></td><td colspan="2" style="vertical-align:top"><p>Trial 2</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Benralizumab</strong></p><p>(n<em><sup>a</sup></em>=267)</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p>(n<em><sup>a</sup></em>=267)</p></td><td style="vertical-align:top"><p><strong>Benralizumab</strong></p><p>(n<em><sup>a</sup></em>=239)</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p>(n<em><sup>a</sup></em>=248)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Total asthma symptom score<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p></td><td style="vertical-align:top"><p>2.68</p></td><td style="vertical-align:top"><p>2.74</p></td><td style="vertical-align:top"><p>2.76</p></td><td style="vertical-align:top"><p>2.71</p></td></tr><tr><td style="vertical-align:top"><p>Improvement from baseline</p></td><td style="vertical-align:top"><p>-1.30</p></td><td style="vertical-align:top"><p>-1.04</p></td><td style="vertical-align:top"><p>-1.40</p></td><td style="vertical-align:top"><p>-1.16</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>-0.25 (-0.45, -0.06)</p></td><td colspan="2" style="vertical-align:top"><p>-0.23 (-0.43, -0.04)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.012</p></td><td colspan="2" style="vertical-align:top"><p>0.019</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>ACQ-6</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p></td><td style="vertical-align:top"><p>2.81</p></td><td style="vertical-align:top"><p>2.90</p></td><td style="vertical-align:top"><p>2.80</p></td><td style="vertical-align:top"><p>2.75</p></td></tr><tr><td style="vertical-align:top"><p>Improvement from baseline</p></td><td style="vertical-align:top"><p>-1.46</p></td><td style="vertical-align:top"><p>-1.17</p></td><td style="vertical-align:top"><p>-1.44</p></td><td style="vertical-align:top"><p>-1.19</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>-0.29 (-0.48, -0.10)</p></td><td colspan="2" style="vertical-align:top"><p>-0.25 (-0.44, -0.07)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>AQLQ(S)+12</strong><strong><sup> </sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline</p></td><td style="vertical-align:top"><p>3.93</p></td><td style="vertical-align:top"><p>3.87</p></td><td style="vertical-align:top"><p>3.87</p></td><td style="vertical-align:top"><p>3.93</p></td></tr><tr><td style="vertical-align:top"><p>Improvement from baseline</p></td><td style="vertical-align:top"><p>1.56</p></td><td style="vertical-align:top"><p>1.26</p></td><td style="vertical-align:top"><p>1.56</p></td><td style="vertical-align:top"><p>1.31</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.30 (0.10, 0.50)</p></td><td colspan="2" style="vertical-align:top"><p>0.24 (0.04, 0.45)</p></td></tr></tbody></table><p><sup>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Number of patients (n) varies slightly due to the number of patients for whom data were available for each variable. Results shown based on last available data for each variable.</p><p><sup>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Asthma symptom scale: total score from 0 (least) to 6 (most); day and night time asthma symptom scores from 0 (least) to 3 (most) symptoms. Individual day and night time scores were similar.&nbsp;</p><p>&nbsp;</p><p><em><u>Subgroup analyses by prior exacerbation history</u></em></p><p>Subgroup analyses from Trials 1 and 2 identified patients with higher prior exacerbation history as a potential predictor of improved treatment response. When considered alone or in combination with baseline blood eosinophils count, these factors may further identify patients who may achieve greater response from benralizumab treatment (<strong>Table 4</strong>).</p><p>&nbsp;</p><p><strong>Table 4. </strong><strong>Exacerbation rate and pulmonary function (FEV<sub>1</sub>) at end of treatment by number of exacerbations in the previous year - Patients on high‑dose ICS and blood eosinophils &ge;300 cells/&mu;L</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:608px"><thead><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Trial 1</p></td><td colspan="2" style="vertical-align:top"><p>Trial 2</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Benralizumab</strong></p><p>(N=267)</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p>(N=267)</p></td><td style="vertical-align:top"><p><strong>Benralizumab</strong></p><p>(N=239)</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p>(N=248)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Baseline of 2 exacerbations</strong></p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>164</p></td><td style="vertical-align:top"><p>149</p></td><td style="vertical-align:top"><p>144</p></td><td style="vertical-align:top"><p>151</p></td></tr><tr><td style="vertical-align:top"><p>Exacerbation rate</p></td><td style="vertical-align:top"><p>0.57</p></td><td style="vertical-align:top"><p>1.04</p></td><td style="vertical-align:top"><p>0.63</p></td><td style="vertical-align:top"><p>0.62</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td colspan="2" style="vertical-align:top"><p>-0.47</p></td><td colspan="2" style="vertical-align:top"><p>0.01</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.55 (0.37, 0.80)</p></td><td colspan="2" style="vertical-align:top"><p>1.01 (0.70, 1.46)</p></td></tr><tr><td style="vertical-align:top"><p>Pre‑bronchodilator FEV<sub>1</sub> mean change</p></td><td style="vertical-align:top"><p>0.343</p></td><td style="vertical-align:top"><p>0.230</p></td><td style="vertical-align:top"><p>0.266</p></td><td style="vertical-align:top"><p>0.236</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.113 (-0.002, 0.228)</p></td><td colspan="2" style="vertical-align:top"><p>0.029 (-0.079, 0.137)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Baseline of 3 or more exacerbations</strong></p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>103</p></td><td style="vertical-align:top"><p>118</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>97</p></td></tr><tr><td style="vertical-align:top"><p>Exacerbation rate</p></td><td style="vertical-align:top"><p>0.95</p></td><td style="vertical-align:top"><p>2.23</p></td><td style="vertical-align:top"><p>0.82</p></td><td style="vertical-align:top"><p>1.65</p></td></tr><tr><td style="vertical-align:top"><p>Difference</p></td><td colspan="2" style="vertical-align:top"><p>-1.28</p></td><td colspan="2" style="vertical-align:top"><p>-0.84</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.43 (0.29, 0.63)</p></td><td colspan="2" style="vertical-align:top"><p>0.49 (0.33, 0.74)</p></td></tr><tr><td style="vertical-align:top"><p>Pre‑bronchodilator FEV<sub>1</sub> mean change</p></td><td style="vertical-align:top"><p>0.486</p></td><td style="vertical-align:top"><p>0.251</p></td><td style="vertical-align:top"><p>0.440</p></td><td style="vertical-align:top"><p>0.174</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.235 (0.088, 0.382)</p></td><td colspan="2" style="vertical-align:top"><p>0.265 (0.115, 0.415)</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Oral corticosteroid dose reduction trials </u></em></p><p>&nbsp;</p><p>ZONDA (Trial 3), a placebo-controlled study, and PONENTE (Trial 6), a single arm, open-label study, evaluated the effect of benralizumab on reducing the use of maintenance OCS.</p><p>&nbsp;</p><p>In Trial 3, the primary endpoint was percent reduction from baseline of the final OCS dose during Weeks 24 to 28, while maintaining asthma control. <strong>Table 5</strong> summarises the study results for Trial 3.</p><p>&nbsp;</p><p><strong>Table 5</strong><strong>. </strong><strong>Effect of benralizumab on OCS dose reduction, Trial 3</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Benralizumab<br />(N=73)</p></td><td style="vertical-align:top"><p>Placebo<br />(N=75)</p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Wilcoxon rank sum test (primary analysis method)</strong></p></td></tr><tr><td><p>Median % reduction in daily OCS dose from baseline (95% CI)</p></td><td><p>75 (60, 88)</p></td><td><p>25 (0, 33)</p></td></tr><tr><td><p>Wilcoxon rank sum test p‑value</p></td><td><p>&lt;0.001</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Proportional odds model (sensitivity analysis)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Percent reduction in OCS from baseline at Week 28</p></td></tr><tr><td style="vertical-align:top"><p>&ge;90% reduction</p></td><td><p>27 (37%)</p></td><td><p>9 (12%)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;75% reduction</p></td><td><p>37 (51%)</p></td><td><p>15 (20%)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;50% reduction</p></td><td><p>48 (66%)</p></td><td><p>28 (37%)</p></td></tr><tr><td style="vertical-align:top"><p>&gt;0% reduction</p></td><td><p>58 (79%)</p></td><td><p>40 (53%)</p></td></tr><tr><td><p>No change or no decrease in OCS</p></td><td><p>15 (21%)</p></td><td><p>35 (47%)</p></td></tr><tr><td><p>Odds ratio (95% CI)</p></td><td><p>4.12 (2.22, 7.63)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Reduction in the daily OCS dose to 0&nbsp;mg/day*</p></td><td><p>22 (52%)</p></td><td><p>8 (19%)</p></td></tr><tr><td><p>Odds ratio (95% CI)</p></td><td><p>4.19 (1.58, 11.12)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Reduction in the daily OCS dose to &le;5&nbsp;mg/day</p></td><td><p>43 (59%)</p></td><td><p>25 (33%)</p></td></tr><tr><td><p>Odds ratio (95% CI)</p></td><td><p>2.74 (1.41, 5.31)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Exacerbation rate</p></td><td><p>0.54</p></td><td><p>1.83</p></td></tr><tr><td><p>Rate ratio (95% CI)</p></td><td><p>0.30 (0.17, 0.53)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Exacerbation rate requiring hospitalisation/emergency room visit</p></td><td><p>0.02</p></td><td><p>0.32</p></td></tr><tr><td><p>Rate ratio (95% CI)</p></td><td><p>0.07 (0.01, 0.63)</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>* </sup>Only patients with an optimised baseline OCS dose of 12.5 mg or less were eligible to achieve a 100% reduction in OCS dose during the study.</p><p>Lung function, asthma symptom score, ACQ‑6 and AQLQ(S)+12 were also assessed in Trial 3 and showed results similar to those in Trials 1 and 2.</p><p>Trial 6 enrolled 598&nbsp;adult patients with severe asthma (blood eosinophil count &ge;150&nbsp;cells/&mu;L at entry or &ge;300 cells/&mu;L in the past 12&nbsp;months if study entry count was &lt;150&nbsp;cells/&mu;L) who were oral corticosteroid-dependent. The primary endpoints were proportion of patients who eliminated OCS while maintaining asthma control and proportion of patients who achieved a final OCS dose less than or equal to 5&nbsp;mg while maintaining asthma control and taking into account adrenal function. The proportion of patients who eliminated maintenance OCS was 62.9%. The proportion of patients who achieved an OCS dose less than or equal to 5&nbsp;mg (while maintaining asthma control and not limited by adrenal function) was 81.9%. Effects on OCS reduction were similar irrespective of blood eosinophil count at study entry (including patients with blood eosinophils &lt;150&nbsp;cells/&mu;L) and maintained over an additional period of 24&nbsp;to&nbsp;32&nbsp;weeks. The annualised exacerbation rate in Trial 6 was comparable to that reported in previous trials.</p><p>&nbsp;</p><p><em><u>Long‑term extension trials</u></em></p><p>The long-term efficacy and safety of benralizumab was evaluated in a phase&nbsp;3, 56‑week extension trial BORA (Trial&nbsp;4). The trial enrolled 2123&nbsp;patients, 2037&nbsp;adults and 86&nbsp;adolescent patients (aged 12&nbsp;years and older) from Trials&nbsp;1, 2 and 3. Trial&nbsp;4 assessed the long-term effect of benralizumab on annual exacerbation rate, lung function, ACQ-6, AQLQ(S)+12 and maintenance of OCS reduction at the 2&nbsp;dose regimens studied in the predecessor studies.</p><p>At the recommended dose regimen, the reduction in annual rate of exacerbations observed in the placebo-controlled predecessor Trials&nbsp;1 and 2 (in patients with baseline blood eosinophil counts &ge;300&nbsp;cells/&mu;L who were taking high‑dose ICS) was maintained over the second year of treatment (<strong>Table&nbsp;6</strong>). In patients who received benralizumab in predecessor Trials&nbsp;1 and 2, 73% were exacerbation‑free in the extension Trial&nbsp;4.</p><p>&nbsp;</p><p><strong>Table 6</strong><strong>. </strong><strong>Exacerbations over an extended treatment period<sup>a</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:608px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo<sup>b</sup></p><p>(N=338)</p></td><td colspan="3" style="vertical-align:top"><p>Benralizumab</p><p>(N=318)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Trial 1 &amp; 2</strong></p></td><td style="vertical-align:top"><p><strong>Trial 1 &amp; 2</strong></p></td><td style="vertical-align:top"><p><strong>Trial 4</strong></p></td><td style="vertical-align:top"><p><strong>Trial 1, 2 &amp; 4<sup>c</sup></strong></p></td></tr><tr><td><p>Rate</p></td><td><p>1.23</p></td><td><p>0.65</p></td><td><p>0.48</p></td><td><p>0.56</p></td></tr></tbody></table><p><sup>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Patients that entered Trial&nbsp;4 from predecessor Trials 1 and 2 with baseline blood eosinophil counts &ge;300&nbsp;cells/&mu;L who were taking high-dose ICS.</p><p><sup>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Placebo patients in Trials&nbsp;1 and 2 are included up to the end of the predecessor trial (Week&nbsp;48 in Trial&nbsp;1, Week&nbsp;56 in Trial&nbsp;2).</p><p><sup>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Total duration of treatment: 104 &ndash; 112&nbsp;weeks</p><p>&nbsp;</p><p>Similar maintenance of effect was observed throughout Trial&nbsp;4 in lung function, ACQ-6 and AQLQ(S)+12 (<strong>Table&nbsp;7</strong>).</p><p>&nbsp;</p><p><strong>Table 7.</strong><strong> </strong><strong>Change from baseline for lung function, ACQ-6, and AQLQ(S)+12<sup>a</sup></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Trial 1 &amp; 2 Baseline<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>Trial 1 &amp; 2 EOT<sup>c</sup></strong></p></td><td style="vertical-align:top"><p><strong>Trial 4 EOT<sup>d</sup> </strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Pre-bronchodilator FEV<sub>1</sub> (L)</strong></p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>318</p></td><td style="vertical-align:top"><p>305</p></td><td style="vertical-align:top"><p>290</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline (SD)</p></td><td style="vertical-align:top"><p>1.741 (0.621)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (SD)<sup> e</sup></p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>0.343 (0.507)</p></td><td style="vertical-align:top"><p>0.404 (0.555)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ACQ-6</strong></p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>318</p></td><td style="vertical-align:top"><p>315</p></td><td style="vertical-align:top"><p>296</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline (SD)</p></td><td style="vertical-align:top"><p>2.74 (0.90)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (SD)<sup> e</sup></p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>-1.44 (1.13)</p></td><td style="vertical-align:top"><p>-1.47 (1.05)</p></td></tr><tr><td style="vertical-align:top"><p><strong>AQLQ(S)+12</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>307</p></td><td style="vertical-align:top"><p>306</p></td><td style="vertical-align:top"><p>287</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline (SD)</p></td><td style="vertical-align:top"><p>3.90 (0.99)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (SD)<sup> e</sup></p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>1.58 (1.23)</p></td><td style="vertical-align:top"><p>1.61 (1.21)</p></td></tr></tbody></table><p>n= number of patients with data at timepoint. SD = standard deviation</p><p>a. Baseline blood eosinophil counts &ge;300&nbsp;cells/&mu;L and taking high-dose ICS: benralizumab administered at the recommended dose regimen.</p><p>b. Integrated analysis of Trial&nbsp;1 and 2 baseline includes adults and adolescents.<br />c. Integrated analysis at End of Treatment (EOT) of Trial&nbsp;1 (Week&nbsp;48) and Trial&nbsp;2 (Week&nbsp;56).<br />d. EOT for Trial&nbsp;4 was Week&nbsp;48 (the last timepoint for adults and adolescent data).</p><p>e. Baseline is prior to benralizumab treatment in Trial&nbsp;1 and 2.</p><p>Efficacy in Trial&nbsp;4 was also evaluated in patients with baseline blood eosinophil counts &lt;300&nbsp;cells/&micro;L and was consistent with Trials&nbsp;1 and 2.</p><p>Maintenance of the reduction in daily OCS dose was also observed over the extension trial in patients enrolled from Trial&nbsp;3 (<strong>Figure&nbsp;1</strong>).</p><p><strong>Figure 1. Median percent reductions in daily OCS over time (Trial&nbsp;3 and 4)<sup>a</sup></strong></p><p>&nbsp;</p><p><strong><sup><img alt="" width="780" height="405" src="data:image/png;base64,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" /></sup></strong></p><ol><li>Predecessor Trial&nbsp;3 patients who continued benralizumab treatment into Trial&nbsp;4. Patients were permitted to enter a second extension trial after a minimum of 8&nbsp;weeks in Trial&nbsp;4 without completing the 56‑week extension period.</li></ol><p>In Trial 5, a second long-term safety extension study (see section 4.8), the annualised exacerbation rate (0.47) in patients receiving the approved dose regimen was comparable to that reported in the predecessor Trials 1, 2 (0.65) and 4 (0.48).</p><p>&nbsp;</p><p><em><u>Eosinophilic granulomatosis with polyangiitis (EGPA)</u></em></p><p>&nbsp;</p><p>The efficacy of benralizumab was evaluated in a randomised, double-blind, active-controlled, non‑inferiority clinical trial of 52-weeks treatment duration, in patients aged 18 years and older with EGPA. A total of 140 patients were randomised to receive either 30 mg of benralizumab or 300 mg of mepolizumab administered subcutaneously every 4 weeks. Patients enrolled had a history of relapsing or refractory disease and were on stable OCS therapy (OCS; &ge;7.5 to &le;50 mg/day prednisolone/prednisone), with or without stable immunosuppressant therapy (excluding cyclophosphamide). The median baseline OCS daily dose was 10 mg and 36% were receiving immunosuppressive therapy. The OCS dose was tapered at the discretion of the investigator. Patients with active organ threatening or life-threatening EGPA were excluded from the trial.</p><p>&nbsp;</p><p><em>Remission</em></p><p>The primary endpoint was the proportion of subjects in remission, defined as Birmingham Vasculitis Activity Score (BVAS)=0 (no active vasculitis) plus prednisolone/prednisone dose &le;4 mg/day, at both Week 36 and Week 48. As shown in Table 8, benralizumab demonstrated non-inferiority to mepolizumab for the primary endpoint. Results for accrued duration of remission and the components of remission are also shown in Table 8.</p><p>&nbsp;</p><p><strong>Table 8. Remission and components of remission in EGPA</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Remission</strong></p><p><strong>(OCS&le;4 mg/day +</strong><br /><strong>&nbsp;BVAS=0)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>OCS&le;4 mg/day</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>BVAS=0</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Benra<sup>a</sup></strong></p><p><strong>N=70</strong></p></td><td style="vertical-align:top"><p><strong>Mepo<sup>b</sup></strong></p><p><strong>N=</strong><strong>70</strong></p></td><td style="vertical-align:top"><p><strong>Benra<sup>a</sup></strong></p><p><strong>N=70</strong></p></td><td style="vertical-align:top"><p><strong>Mepo<sup>b</sup></strong></p><p><strong>N=</strong><strong>70</strong></p></td><td style="vertical-align:top"><p><strong>Benra<sup>a</sup></strong></p><p><strong>N=70</strong></p></td><td style="vertical-align:top"><p><strong>Mepo<sup>b</sup></strong></p><p><strong>N=</strong><strong>70</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Patients in remission at both Weeks 36 and 48</strong></p></td></tr><tr><td style="vertical-align:top"><p>Patients, n (%)<sup>c</sup></p></td><td style="vertical-align:top"><p>40 (58)</p></td><td style="vertical-align:top"><p>40 (57)</p></td><td style="vertical-align:top"><p>42 (61)</p></td><td style="vertical-align:top"><p>41 (58)</p></td><td style="vertical-align:top"><p>58 (83)</p></td><td style="vertical-align:top"><p>59 (84)</p></td></tr><tr><td style="vertical-align:top"><p>Differences in remission rate (%)<sup>c</sup></p><p>(95% CI)</p><p>(p-value)</p></td><td colspan="2" style="vertical-align:top"><p>1.21</p><p>&nbsp;</p><p>(-14.12, 16.53)</p><p>(0.88)<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>2.64</p><p>&nbsp;</p><p>(-12.67, 17.95)</p><p>(0.74)<sup>d e</sup></p></td><td colspan="2" style="vertical-align:top"><p>-1.17</p><p>&nbsp;</p><p>(-13.27, 10.94)</p><p>(0.85)<sup>d e</sup></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Accrued duration over 52</strong> <strong>weeks, n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>0 weeks<sup>f</sup></p><p>&gt;0 to &lt;12 weeks</p><p>12 to &lt;24 weeks</p><p>24 to &lt;36 weeks</p><p>&ge;36 weeks</p></td><td style="vertical-align:top"><p>9 (13)</p><p>13 (19)</p><p>8 (11)</p><p>20 (29)</p><p>20 (29)</p></td><td style="vertical-align:top"><p>15 (21)</p><p>10 (14)</p><p>8 (11)</p><p>19 (27)</p><p>18 (26)</p></td><td style="vertical-align:top"><p>9 (13)</p><p>11 (16)</p><p>9 (13)</p><p>19 (27)</p><p>22 (31)</p></td><td style="vertical-align:top"><p>12 (17)</p><p>12 (17)</p><p>8 (11)</p><p>18 (26)</p><p>20 (29)</p></td><td style="vertical-align:top"><p>0</p><p>0</p><p>2 (3)</p><p>6 (9)</p><p>62 (89)</p></td><td style="vertical-align:top"><p>0</p><p>2 (3)</p><p>2 (3)</p><p>7 (10)</p><p>59 (84)</p></td></tr></tbody></table><p>N=number of patients in analysis.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benralizumab (Benra) 30 mg administered every 4 weeks.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mepolizumab (Mepo) 300 mg administered every 4 weeks.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Model adjusted percentages.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Used for superiority testing.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not formally tested in a pre-specified multiplicity testing procedure.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Did not achieve remission at any point.</p><p>&nbsp;</p><p>The proportion of patients achieving remission within the first 24 weeks of treatment and remaining in remission through Week 52 was 42% for benralizumab and 37% for mepolizumab (difference in responder rate 5.54%, 95% CI: -9.30, 20.37, nominal p-value 0.46).</p><p>&nbsp;</p><p>Using an alternative remission definition of BVAS=0 plus prednisolone/prednisone &le;7.5 mg/day, a consistent efficacy between groups for these endpoints was observed.</p><p>&nbsp;</p><p>Patients achieved the primary remission endpoint across the prespecified demographic and baseline characteristic subgroups.</p><p>&nbsp;</p><p><em>Relapse</em></p><p>The hazard ratio for time to first relapse (vasculitis, asthma, or sino-nasal) was 0.98 (95% CI: 0.53, 1.82, nominal p-value 0.95). Relapse was observed in 30% of patients on benralizumab and 30% of patients on mepolizumab. The annualised relapse rate was 0.50 for patients receiving benralizumab versus 0.49 for patients receiving mepolizumab (rate ratio 1.03, 95% CI: 0.56, 1.90, nominal p-value 0.93). The types of relapse were consistent for patients receiving benralizumab or mepolizumab.</p><p>&nbsp;</p><p><em>Oral corticosteroids</em></p><p>The average daily OCS dose during Weeks 48 to 52 is presented in Table 9. A 100% reduction in the OCS dose was observed in 41% of patients receiving benralizumab compared to 26% of those receiving mepolizumab (difference 15.69%, 95% CI: 0.67, 30.71, nominal p-value 0.04).</p><p><em>&nbsp;</em></p><p><strong>Table 9.</strong> <strong>Average daily oral corticosteroid dose during weeks 48 to 52 in EGPA</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Benralizumab<sup>a</sup> (N=70)</strong></p></td><td style="vertical-align:top"><p><strong>Mepolizumab<sup>b</sup> (N=70)</strong></p></td></tr><tr><td style="vertical-align:top"><p>0 mg</p><p>&gt;0 to &le;4.0 mg</p><p>&gt;4.0 to &le;7.5 mg</p><p>&gt;7.5 mg</p></td><td style="vertical-align:top"><p>29 (41)</p><p>19 (27)</p><p>15 (21)</p><p>7 (10)</p></td><td style="vertical-align:top"><p>19 (27)</p><p>30 (43)</p><p>13 (19)</p><p>8 (11)</p></td></tr></tbody></table><p>N=number of patients in analysis.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benralizumab 30 mg administered every 4 weeks.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mepolizumab 300 mg administered every 4 weeks.</p><p>&nbsp;</p><p><em>Asthma Control Questionnaire-6 (ACQ-6)</em></p><p>The ACQ-6 mean change from baseline was -0.57 for benralizumab versus -0.61 for mepolizumab (difference 0.05, 95% CI: -0.18, 0.27, nominal p-value 0.67).</p><p>&nbsp;</p><p><u style="text-align:unset">Immunogenicity</u></p><p>Overall, treatment‑emergent anti‑drug antibody (ADA) response developed in 107 out of 809 (13%) patients with asthma treated with benralizumab at the recommended dose regimen during the 48 to 56 week treatment period of the phase 3 placebo-controlled exacerbation trials. Most antibodies were neutralising and persistent. Anti‑benralizumab antibodies were associated with increased clearance of benralizumab and increased blood eosinophil levels in patients with high ADA titres compared to antibody negative patients; in rare cases, blood eosinophil levels returned to pre‑treatment levels. Based on current patient follow-up, no evidence of an association of ADA with efficacy or safety was observed.</p><p>&nbsp;</p><p>Following a second year of treatment of these patients with asthma from the phase 3 placebo-controlled trials, an additional 18 out of 510 (4%) had newly developed treatment-emergent antibodies. Overall, in patients who were ADA positive in the predecessor trials, titres remained stable or declined in the second year of treatment. No evidence of an association of ADA with efficacy or safety was observed.</p><p>In patients with EGPA, treatment-emergent ADA response developed in 6 out of 67 (9%) patients treated with benralizumab during the Phase 3 active-controlled 52‑week treatment period. Neutralising antibody activity was detected in one of the ADA positive patients.</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p><em><u>Asthma</u></em></p><p>There were 108 adolescents aged 12 to 17 with asthma enrolled in the phase 3 trials (Trial 1: n=53, Trial 2: n=55). Of these, 46 received placebo, 40 received benralizumab every 4&nbsp;weeks for 3&nbsp;doses, followed by every 8&nbsp;weeks thereafter, and 22 received benralizumab every 4&nbsp;weeks. In these trials, the asthma exacerbation rate in adolescent patients treated with benralizumab administered at the recommended dose regimen was 0.70 (n=40, 95% CI: 0.42, 1.18) compared to 0.41 for placebo (n=46, 95% CI: 0.23, 0.73) [rate ratio 1.70, 95% CI: 0.78, 3.69].</p><p>Adolescent patients aged&nbsp;12 to 17 (n=86) from Trials&nbsp;1 and 2 continued treatment with benralizumab in Trial&nbsp;4 for up to 108&nbsp;weeks. Efficacy and safety were consistent with the predecessor trials.</p><p>In an open-label, uncontrolled pharmacokinetic and pharmacodynamic study of 48 weeks duration in a</p><p>limited number of patients 6 to 11 years (n=28) with uncontrolled severe asthma, the magnitude of</p><p>blood eosinophil depletion was similar to adults and adolescents.</p><p>No conclusion can be drawn regarding asthma efficacy in the paediatric population (see section 4.2).</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with benralizumab in one or more subsets of the paediatric population in asthma (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p><em>Eosinophilic granulomatosis with polyangiitis (EGPA)</em></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with benralizumab in one or more subsets of the paediatric population in EGPA (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of benralizumab below are based on the population pharmacokinetics analyses from the asthma trials. The pharmacokinetics of benralizumab were dose‑proportional in patients with asthma following subcutaneous administration over a dose range of 2 to 200 mg.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Following subcutaneous administration to patients with asthma, the absorption half‑life was 3.5&nbsp;days. Based on population pharmacokinetic analysis, the estimated absolute bioavailability was approximately 59% and there was no clinically relevant difference in relative bioavailability in the administration to the abdomen, thigh, or upper arm.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Based on population pharmacokinetic analysis, central and peripheral volume of distribution of benralizumab was 3.1 L and 2.5 L, respectively, for a 70&nbsp;kg individual.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Benralizumab is a humanised IgG1 monoclonal antibody that is degraded by proteolytic enzymes widely distributed in the body and not restricted to hepatic tissue.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>From population pharmacokinetic analysis, benralizumab exhibited linear pharmacokinetics and no evidence of target receptor‑mediated clearance pathway. The estimated systemic clearance (CL) for benralizumab was at 0.29 L/d. In patients with EGPA, the model estimated systemic clearance was 0.22 L/d. Following subcutaneous administration, the elimination half‑life was approximately 15.5 days.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly (&ge;65&nbsp;years old)</em></p><p>Based on population pharmacokinetic analysis, age did not affect benralizumab clearance. However, no data are available in patients over 75&nbsp;years of age.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>Based on population pharmacokinetic analysis and clinical study data, the pharmacokinetics of benralizumab in children and adolescents aged 6 to 17 years with asthma were consistent with adults after accounting for body weight as applicable (see section 4.2).</p><p><em>&nbsp;</em></p><p><em>Gender, race</em></p><p>A population pharmacokinetics analysis, indicated that there was no significant effect of gender and race on benralizumab clearance.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No formal clinical studies have been conducted to investigate the effect of renal impairment on benralizumab. Based on population pharmacokinetic analysis, benralizumab clearance was comparable in subjects with creatinine clearance values between 30 and 80&nbsp;mL/min and patients with normal renal function. There are limited data available in subjects with creatinine clearance values less than 30&nbsp;mL/min; however, benralizumab is not cleared renally.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No formal clinical studies have been conducted to investigate the effect of hepatic impairment on benralizumab. IgG monoclonal antibodies are not primarily cleared via hepatic pathway; change in hepatic function is not expected to influence benralizumab clearance. Based on population pharmacokinetic analysis, baseline hepatic function biomarkers (ALT, AST, and bilirubin) had no clinically relevant effect on benralizumab clearance.</p><p>&nbsp;</p><p><em>Interaction</em></p><p>Based on the population pharmacokinetic analysis, commonly co‑administered medicinal products (montelukast, paracetamol, proton pump inhibitors, macrolides and theophylline/aminophylline) had no effect on benralizumab clearance in patients with asthma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As benralizumab is a monoclonal antibody, no genotoxicity or carcinogenicity studies have been conducted.</p><p>&nbsp;</p><p><u>Animal toxicology and/or pharmacology</u></p><p>Non‑clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology or repeated dose toxicity studies in monkeys. Intravenous and subcutaneous administration to cynomolgus monkeys was associated with reductions in peripheral blood and bone marrow eosinophil counts, with no toxicological findings.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>In a prenatal and postnatal development study in pregnant cynomolgus monkeys, there were no benralizumab‑related maternal, embryo‑foetal, or postnatal effects observed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No dedicated animal studies have been conducted. No benralizumab‑related impairment was observed in reproductive parameters of male and female cynomolgus monkeys. Examination of surrogate fertility parameters (including organ weights and histopathology of reproductive tissues) in animals treated with benralizumab suggested no impairment of fertility. However, in the offspring of monkeys dosed while pregnant, there was a reduction in eosinophils.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Histidine</p><p>Histidine hydrochloride monohydrate</p><p>Trehalose dihydrate</p><p>Polysorbate 20 (E 432)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C to 8&nbsp;&deg;C).</p><p>Fasenra may be kept at room temperature up to 25&nbsp;&deg;C for a maximum of 14&nbsp;days. After removal from the refrigerator, Fasenra must be used within 14&nbsp;days or discarded.</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>Do not freeze. Do not shake. Do not expose to heat.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre‑filled syringe</u></p><p>One&nbsp;mL solution in a single‑use pre‑filled syringe made from type I glass with a staked 29‑gauge &frac12;‑inch (12.7&nbsp;mm) stainless steel needle, rigid needle shield, and Fluorotec‑coated plunger stopper in a passive safety device.</p><p>Pack containing 1 pre‑filled syringe.</p><p>&nbsp;</p><p><u>Pre‑filled pen</u></p><p>One&nbsp;mL solution in a sterile, single use pre‑filled pen made from type I glass with staked 29‑gauge &frac12;‑inch (12.7&nbsp;mm) stainless steel needle, rigid needle shield, and Fluorotec‑coated stopper in a pre‑filled pen.</p><p>Pack containing 1 pre‑filled pen.</p><p>&nbsp;</p><p>Not all presentations may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prior to administration, allow the pre-filled syringe or pre-filled pen to reach room temperature 20&nbsp;&deg;C to 25&nbsp;&deg;C by leaving the carton out of the refrigerator for around 30&nbsp;minutes.</p><p>Visually inspect Fasenra for particulate matter and discolouration prior to administration. Fasenra is clear to opalescent, colourless to yellow, and may contain translucent or white to off‑white particles. Do not use Fasenra if liquid is cloudy, discoloured, or if it contains large particles or foreign particulate matter.</p><p>Additional information and instructions for the preparation and administration of Fasenra using the pre‑filled syringe or pre‑filled pen are given in the package leaflet and &lsquo;Instructions for Use&rsquo;.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca AB
SE- 151 85 
Södertälje
Sweden
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>